Literature DB >> 24793737

Vasodilators, blood pressure-lowering medications, and age-related macular degeneration: the Beaver Dam Eye Study.

Ronald Klein1, Chelsea E Myers2, Barbara E K Klein2.   

Abstract

OBJECTIVE: To examine the association of vasodilator and antihypertensive medication use with the incidence of age-related macular degeneration (AMD).
DESIGN: Longitudinal population-based study. PARTICIPANTS: Persons 43 to 86 years of age living in Beaver Dam, Wisconsin, from 1988 through 1990.
METHODS: Examinations were performed every 5 years over a 20-year period. There were 9676 total person-visits over the course of the study. Status of AMD was determined from grading retinal photographs. MAIN OUTCOME MEASURES: Incidence of AMD.
RESULTS: The 5-year incidence of early AMD over the 20-year period was 8.4%; for late AMD, it was 1.4%; for pure geographic atrophy (GA), it was 0.6%; for exudative AMD, it was 0.9%; and for progression of AMD, it was 24.9%. While adjusting for age, gender, and other factors, using a vasodilator (hazard ratio [HR], 1.72; 95% confidence interval [CI], 1.25-2.38), particularly oral nitroglycerin (HR, 1.81; 95% CI, 1.14-2.90), was associated with an increased risk of early AMD. Using an oral β-blocker was associated with an increased hazard of incident exudative AMD (HR, 1.71; 95% CI, 1.04-2.82), but not pure GA (HR, 0.51; 95% CI, 0.20-1.29) or progression of AMD (HR, 0.92; 95% CI, 0.67-1.28) over the 20-year period.
CONCLUSIONS: Use of vasodilators is associated with a 72% increase in the hazard of incidence of early AMD, and use of oral β-blockers is associated with a 71% increase in the hazard of incident exudative AMD. If these findings are replicated, it may have implications for care of older adults because vasodilators and oral β-blockers are drugs that are used commonly by older persons.
Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24793737      PMCID: PMC4122609          DOI: 10.1016/j.ophtha.2014.03.005

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  31 in total

1.  Update of the vascular model of AMD.

Authors:  E Friedman
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

2.  The Wisconsin age-related maculopathy grading system.

Authors:  R Klein; M D Davis; Y L Magli; P Segal; B E Klein; L Hubbard
Journal:  Ophthalmology       Date:  1991-07       Impact factor: 12.079

Review 3.  Sildenafil (Viagra) and ophthalmology.

Authors:  M F Marmor; R Kessler
Journal:  Surv Ophthalmol       Date:  1999 Sep-Oct       Impact factor: 6.048

4.  Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study.

Authors:  R Klein; B E Klein; S C Jensen; K J Cruickshanks; K E Lee; L G Danforth; S C Tomany
Journal:  Arch Ophthalmol       Date:  2001-09

5.  Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group.

Authors:  L Hyman; A P Schachat; Q He; M C Leske
Journal:  Arch Ophthalmol       Date:  2000-03

6.  Changes in visual acuity in a population over a 10-year period : The Beaver Dam Eye Study.

Authors:  R Klein; B E Klein; K E Lee; K J Cruickshanks; R J Chappell
Journal:  Ophthalmology       Date:  2001-10       Impact factor: 12.079

7.  Harmonizing the classification of age-related macular degeneration in the three-continent AMD consortium.

Authors:  Ronald Klein; Stacy M Meuer; Chelsea E Myers; Gabriëlle H S Buitendijk; Elena Rochtchina; Farzana Choudhury; Paulus T V M de Jong; Roberta McKean-Cowdin; Sudha K Iyengar; Xiaoyi Gao; Kristine E Lee; Johannes R Vingerling; Paul Mitchell; Caroline C W Klaver; Jie Jin Wang; Barbara E K Klein
Journal:  Ophthalmic Epidemiol       Date:  2014-02       Impact factor: 1.648

8.  Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from 3 continents.

Authors:  Redmer van Leeuwen; Sandra C Tomany; Jie Jin Wang; Ronald Klein; Paul Mitchell; Albert Hofman; Barbara E K Klein; Johannes R Vingerling; Robert G Cumming; Paulus T V M de Jong
Journal:  Ophthalmology       Date:  2004-06       Impact factor: 12.079

9.  The Beaver Dam Eye Study: visual acuity.

Authors:  R Klein; B E Klein; K L Linton; D L De Mets
Journal:  Ophthalmology       Date:  1991-08       Impact factor: 12.079

10.  Effect of topical timolol on the human retinal circulation.

Authors:  J E Grunwald
Journal:  Invest Ophthalmol Vis Sci       Date:  1986-12       Impact factor: 4.799

View more
  11 in total

Review 1.  Differential Gene Expression in Age-Related Macular Degeneration.

Authors:  Denise J Morgan; Margaret M DeAngelis
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-23       Impact factor: 6.915

2.  EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS.

Authors:  Ehsan Rahimy; Gui-Shuang Ying; Wei Pan; Jason Hsu
Journal:  Retina       Date:  2019-04       Impact factor: 4.256

3.  Association of Anticholinergic Drug Use With Risk for Late Age-Related Macular Degeneration.

Authors:  Gauthier Aldebert; Jean-Luc Faillie; Dominique Hillaire-Buys; Thibault Mura; Isabelle Carrière; Cécile Delcourt; Catherine Creuzot-Garcher; Max Villain; Vincent Daien
Journal:  JAMA Ophthalmol       Date:  2018-07-01       Impact factor: 7.389

4.  SYSTEMIC BETA-BLOCKERS AND RISK OF PROGRESSION TO NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Authors:  Anton M Kolomeyer; Maureen G Maguire; Wei Pan; Brian L VanderBeek
Journal:  Retina       Date:  2019-05       Impact factor: 4.256

5.  SYSTEMIC BETA-BLOCKERS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Authors:  Anastasia Traband; James A Shaffer; Brian L VanderBeek
Journal:  Retina       Date:  2017-01       Impact factor: 4.256

6.  The flicker response of venous oxygen saturation is significantly reduced in the early and late stages of age-related macular degeneration.

Authors:  Emilia Donicova; L Ramm; R Augsten; M Hammer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-28       Impact factor: 3.117

7.  SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.

Authors:  Delu Song; Peiying Hua; Brian L VanderBeek; Joshua L Dunaief; Juan E Grunwald; Ebenezer Daniel; Maureen G Maguire; Daniel F Martin; Gui-Shuang Ying
Journal:  Retina       Date:  2021-07-01       Impact factor: 3.975

Review 8.  Intake of dietary salt and drinking water: Implications for the development of age-related macular degeneration.

Authors:  Andreas Bringmann; Margrit Hollborn; Leon Kohen; Peter Wiedemann
Journal:  Mol Vis       Date:  2016-12-22       Impact factor: 2.367

9.  Promiscuous Chemokine Antagonist (BKT130) Suppresses Laser-Induced Choroidal Neovascularization by Inhibition of Monocyte Recruitment.

Authors:  Shira Hagbi-Levi; Michal Abraham; Liran Tiosano; Batya Rinsky; Michelle Grunin; Orly Eizenberg; Amnon Peled; Itay Chowers
Journal:  J Immunol Res       Date:  2019-08-05       Impact factor: 4.818

10.  Age-Related Macular Degeneration and Associated Risk Factors in the Population-Based Study of Health in Pomerania (SHIP-Trend).

Authors:  Lisa Lüdtke; Clemens Jürgens; Till Ittermann; Henry Völzke; Frank Tost
Journal:  Med Sci Monit       Date:  2019-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.